ERBB2 and breast cancer: Pyrotinib, an irreversible TKI of HER1, HER2, and HER4, was conditionally approved in 2018 in China for treatment in combination with capecitabine of advanced metastatic HER2-positive breast cancer previously treated with standard anthracycline or taxane chemotherapy [41,48].